Biotech company Moderna wants to sell a dose of the coronavirus vaccine for $25-30, sources close to the company's negotiations with potential buyers told the Financial Times (FT). The course of vaccinations will cost $50-60. This price can be set for the United States and other high-income countries.
According to the newspaper, this cost causes “difficulties in negotiations” because other manufacturers are willing to sell the vaccine cheaper. Probably, Moderna will still change the price of the course of vaccinations. The FT cites the cost of other developer's vaccines. So, American Pfizer and German BioNTtech are ready to sell 100 million doses to the US for $19.5. British-Swedish AstraZeneca set the cost at $3-4.
Moderna this week started the third phase of clinical trials of the COVID-19 vaccine. 30 thousand volunteers will take part in it. This is the largest testing in the world.
Developers of the Russian vaccine are completing the second phase of clinical trials. This was reported in the Ministry of health. The Agency clarified that the issue of state registration of the vaccine will be decided when the tests are over.
Add a comment!